Results 81 to 90 of about 29,283 (270)
Head &Neck, EarlyView.ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) lacks an established screening program, and most cases are diagnosed at advanced stages. Multi‐cancer early detection (MCED) blood‐based assays represent a promising approach, yet real‐world clinical experience with MCED‐identified HNSCC remains limited.
Abhinav Talwar +3 more
wiley +1 more source
Circulating Tumor DNA in Primary and Secondary Liver Cancers: A Comprehensive Review
Frontiers in Bioscience-ScholarSimilar to many other cancer types, liver malignancies pose the common challenges of late detection of primary tumors and recurrences. Liquid biopsies, which assess the presence of circulating tumor DNA, have emerged as a novel, non-invasive clinical ...
Hanna Hong +15 more
doaj +1 more source
Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. [PDF]
, 2020 BACKGROUND DNA originating from degenerate tumour cells can be detected in the circulation in many tumour types, where it can be used as a marker of disease burden as well as to monitor treatment response.
Kwan, Edmond M +19 more
core +2 more sources
International Journal of Cancer, EarlyView.What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto +21 more
wiley +1 more source
International Journal of Cancer, EarlyView.While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva +25 more
wiley +1 more source
Expanding the clinical uses of ctDNA
Practical oncology, 2021 The majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal with the detection of mutations. The analysis of cfDNA is often discussed in the context of the noninvasive detection of mutations that lead to resistance mechanisms and therapeutic and disease monitoring in cancer patients.
openaire +1 more source
Abstract 744: ctDNA use in molecular diagnostics
, 2017 The analysis of circulating cell-free tumor DNA (ctDNA), which can be obtained from plasma by non-invasive procedures, is expected to provide useful biomarkers in the management of non-small-cell lung cancer (NSCLC) patients. Indeed, several studies have
Elena DalCin +10 more
core +1 more source
Dataset of RNAseq, TCR and ctDNA
, 2021 This dataset includes gene expression matrix by TPM normalization, TCR clonality and ctDNA ...
Jianming Xu (11288670)
core +1 more source
De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer
International Journal of Cancer, EarlyView.ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT The incidence of human papillomavirus‐positive (HPV+) oropharyngeal cancer (OPC) has increased rapidly, and HPV early antigen serology has been proposed as a scalable and cost‐effective early detection test. HPV seropositivity can precede clinical presentation of OPC by several years, so additional surveillance procedures may be necessary to ...
Lucas Penny +23 more
wiley +1 more source